FGFR1 alpha Antibody (1058809) [Alexa Fluor® 488]

• Reactivity: Hu
• Applications: Flow
• Clone: 1058809
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 488

FGFR1 alpha Antibody (1058809) [Alexa Fluor® 488] Summary

• Immunogen: Human embryonic kidney cell, HEK293-derived human FGFR1 alpha
  Arg22-Glu376
  Accession # P11362.3
• Specificity: Detects human FGFR1 alpha (IIIc) in direct ELISA.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for FGFR1 alpha Antibody (1058809) [Alexa Fluor® 488]

• FGF R1a
• FGFR1 alpha

Background

Fibroblast growth factor receptor 1 (FGFR1) belongs to a family of type I transmembrane tyrosine kinases which mediate the biological functions of FGFs that are involved in a multitude of physiological and pathological cellular processes (1). The FGFR family is comprised of 4 structurally conserved members (FGFR1-4) all possessing an extracellular domain (ECD) with three immunoglobulin (Ig)-like domains, an acid-box region containing a run of acidic residues between the IgI and IgII domains, a transmembrane domain and cytoplasmic split tyrosine-kinase domain (1, 2). The ECD of mature, full-length FGFR1 shares 98% amino acid sequence identity with mouse FGFR1. Alternative splicing generates multiple forms of FGFR1-3, each with unique signaling characteristics (1-3). For FGFR1, alternative splicing of the ECD generates FGFR1A, FGFR1B, and FGFR1G isoforms of the receptor with the A isoform containing three Ig domains, while the B and G isoforms lack the N‑terminal IgI domain (3). Additional splicing of the IgIII domain, results in IIIa, IIIb, or IIIc isoforms (3). Only the alpha isoform has been identified for FGFR3 and FGFR4 and FGFR4 also lacks the IIIb and IIIc splicing events (4). The FGFR splice variants also exhibit distinct and varying binding affinities for different FGF ligands (2). FGFRs mediate the FGF signaling cascade which regulate developmental processes including cellular proliferation, differentiation, and migration, morphogenesis, and patterning (5). FGFRs transduce the signals through three dominant pathways including RAS/MAPK, PI3k/AKT, and PLC gamma (6). FGFR1 the most abundant FGFR and is widely expressed in many adult human tissues, but the splice variants display distinct tissue-specific differences with IIIc splice variants expressed in mesenchymal tissue (4, 7, 8). Mutations in FGFR1 or misregulation of FGFR1 mediated signaling is found in multiple diseases, with FGFR1A(IIIc) specifically upregulated, from breast and pancreatic cancer to Pfeiffer syndrome and osteoarthritis (4, 9-11). A soluble version of the FGFR1A(IIIc) splice variant has shown anti-angiogenic and anti-proliferative properties in multiple cancer cell line models (11).

1. Ornitz, D.M. and Itoh, N. (2015) Wiley Interdiscip. Rev. Dev. Biol. 4:215.
2. Zhang, X. et al. (2006) J Biol. Chem. 281:15694.
3. Ferguson, H.R. et al. (2021) Signaling Cells 10:1201.
4. Holzmann, K. et al. (2012) J Nucleic. Acids 2012:950508.
5. Xie, Y. et al. (2020) Sig. Transduct. Target Ther. 5:181.
6. Mossahebi-Mohammadi, M. et al. (2020) Front Cell Dev. Biol. 18:79.
7. Hughes, S.E. (1997) J. Histochem. Cytochem. 45:1005.
8. Delezoide, A.L. et al. (1998) Mech. Dev. 77:19.
9. Yamashita-Sugahara, Y. et al. (2016) Sci. Rep. 6:35908.
10. Teven, C.M. et al. (2014) Genes Dis. 1:199.
11. Babina, I. and Turner, N. (2017) Nat. Rev Cancer 17:318.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P11362.3()